Intrexon | XON - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agenus USD 6.21M 4.34M 2026-03
Alaunos Therapeutics USD 424K 23K 2026-06
Amgen USD 1.68B 40M 2026-09
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
AstraZeneca USD 4.07B 1.73B 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Heron Therapeutics USD 23.74M 605K 2025-12
Incyte USD 364.27M 12.54M 2026-09
Intrexon USD 10.31M 41K 2024-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Ligand Pharmaceuticals USD 72.62M 43.49M 2026-09
MacroGenics USD 7.9M 1.81M 2026-06
MannKind USD 61.41M 3.11M 2026-09
Merck USD 2.86B 25M 2026-09
Novartis USD 3.08B 163M 2026-09
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Thermo Fisher Scientific USD 1.86B 46M 2026-09
Veracyte USD 57.95M 2.25M 2026-09
Xencor USD 71.93M 5.61M 2026-09